标题
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
作者
关键词
-
出版物
Nature Reviews Endocrinology
Volume 16, Issue 11, Pages 642-653
出版商
Springer Science and Business Media LLC
发表日期
2020-09-15
DOI
10.1038/s41574-020-0399-8
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Use of dipeptidyl peptidase‐4 inhibitors and the risk of arthralgia: Population‐based cohort and nested case–control studies
- (2019) Chen‐Yu Wang et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes
- (2019) Antonios Douros et al. DIABETES CARE
- Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes
- (2019) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Review of cardiovascular outcomes trials of sodium–glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists
- (2019) Emily J. North et al. CURRENT OPINION IN CARDIOLOGY
- Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and malignancies: a meta‐analysis based on cardiovascular outcomes trials
- (2019) Mirna Abd El Aziz et al. DIABETES OBESITY & METABOLISM
- Persistent whole day meal effects of three dipeptidyl peptidase‐4 inhibitors on glycaemia and hormonal responses in metformin‐treated type 2 diabetes
- (2019) Wathik Alsalim et al. DIABETES OBESITY & METABOLISM
- Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials
- (2019) Ilaria Dicembrini et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETOLOGIA
- European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure
- (2019) Petar M. Seferović et al. EUROPEAN JOURNAL OF HEART FAILURE
- Prescription of DPP-4 Inhibitors to Type 2 Diabetes Mellitus Patients With Renal Impairment: A UK Primary Care Experience
- (2018) Dionysis Spanopoulos et al. CLINICAL THERAPEUTICS
- The safety of gliptins : updated data in 2018
- (2018) André Jacques Scheen Expert Opinion On Drug Safety
- The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies
- (2018) María Molina-Vega et al. Expert Opinion On Drug Safety
- Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization
- (2018) Irene García-Díez et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes
- (2018) Carolyn F. Deacon PEPTIDES
- Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure
- (2018) John J.V. McMurray et al. JACC-Heart Failure
- Characteristics of Elderly Patients Initiating Sitagliptin or Non-DPP-4-Inhibitor Oral Antihyperglycemic Agents: Analysis of a Cross-Sectional US Claims Database
- (2018) Tongtong Wang et al. Diabetes Therapy
- Characteristics of Elderly Patients Initiating Sitagliptin or Non-DPP-4-Inhibitor Oral Antihyperglycemic Agents: Analysis of a Cross-Sectional US Claims Database
- (2018) Tongtong Wang et al. Diabetes Therapy
- A Randomized, Double-Blinded, Placebo-Controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed HIV Infection
- (2018) Michael P Dubé et al. CLINICAL INFECTIOUS DISEASES
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETOLOGIA
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
- (2018) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes
- (2018) Chintan N. Koyani et al. Frontiers in Physiology
- Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials
- (2017) Sophia Zoungas et al. Lancet Diabetes & Endocrinology
- Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor
- (2016) David W. Boulton CLINICAL PHARMACOKINETICS
- Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus
- (2016) Carol Addy et al. CLINICAL THERAPEUTICS
- Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist
- (2016) Michael A. Nauck et al. DIABETES
- Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment
- (2016) Oleg Baranov et al. DIABETES OBESITY & METABOLISM
- Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas
- (2016) C. F. Deacon et al. DIABETES OBESITY & METABOLISM
- Drug development from the bench to the pharmacy: with special reference to dipeptidyl peptidase-4 inhibitor development
- (2016) R. D. Carr DIABETIC MEDICINE
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM –2016 EXECUTIVE SUMMARY
- (2016) Alan J. Garber et al. Endocrine Practice
- Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis
- (2016) Laurent Azoulay et al. JAMA Internal Medicine
- Efficacy, safety and impact on β-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and the difference between Asians and Caucasians: a meta-analysis
- (2016) W. Gao et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial
- (2015) Lawrence A. Leiter et al. DIABETES CARE
- Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial
- (2015) Wolfgang Kothny et al. DIABETOLOGIA
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY – CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN – 2015
- (2015) Yehuda Handelsman et al. Endocrine Practice
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study
- (2015) Nobuya Inagaki et al. Lancet Diabetes & Endocrinology
- Hepatotoxicity of Alogliptin
- (2014) Elizabeth Barbehenn et al. CLINICAL PHARMACOKINETICS
- Alogliptin: Concern About Hepatotoxicity?
- (2014) André J. Scheen CLINICAL PHARMACOKINETICS
- Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies
- (2014) Michael Lehrke et al. CLINICAL THERAPEUTICS
- Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes
- (2014) J. Farngren et al. DIABETES OBESITY & METABOLISM
- Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors
- (2014) K. Aaboe et al. DIABETES OBESITY & METABOLISM
- Risk of pancreatitis in patients treated with incretin-based therapies
- (2014) Juris J. Meier et al. DIABETOLOGIA
- Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
- (2014) Erin E. Mulvihill et al. ENDOCRINE REVIEWS
- Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
- (2014) Amy G. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of dipeptidyl-peptidase-4 inhibitors and impact onβ-cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta-analysis在亚洲人和白种人的2型糖尿病患者中DPP-4抑制剂的疗效及对β细胞功能的影响：一项meta分析
- (2014) Xiaoling Cai et al. Journal of Diabetes
- A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site
- (2013) Mika Nabeno et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Defining the Role of GLP-1 in the Enteroinsulinar Axis in Type 2 Diabetes Using DPP-4 Inhibition and GLP-1 Receptor Blockade
- (2013) B. A. Aulinger et al. DIABETES
- A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks
- (2013) M. A. Nauck DIABETES CARE
- A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 therapies safe?
- (2013) P. C. Butler et al. DIABETES CARE
- The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses
- (2013) D. Anz et al. DIABETES OBESITY & METABOLISM
- Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus
- (2013) Boaz Hirshberg et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis
- (2013) Y. G. Kim et al. DIABETOLOGIA
- Glucose-dependent Insulinotropic Polypeptide: Blood Glucose Stabilizing Effects in Patients With Type 2 Diabetes
- (2013) Mikkel B. Christensen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study
- (2013) W David Strain et al. LANCET
- Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial
- (2013) Anthony H Barnett et al. LANCET
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
- (2013) Daniel A. Tatosian et al. Diabetes Therapy
- Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
- (2013) Samuel S. Engel et al. Diabetes Therapy
- Pharmacokinetics of linagliptin in subjects with hepatic impairment
- (2012) Ulrike Graefe-Mody et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin
- (2012) Yan-Ling He CLINICAL PHARMACOKINETICS
- Clinical Pharmacokinetics and Pharmacodynamics of Linagliptin
- (2012) Ulrike Graefe-Mody et al. CLINICAL PHARMACOKINETICS
- Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of dipeptidyl peptidase-IV inhibition
- (2012) M. R. Rizzo et al. DIABETES CARE
- Dipeptidyl Peptidase IV Inhibition Does Not Adversely Affect Immune or Virological Status in HIV Infected Men And Women: A Pilot Safety Study
- (2012) Scott R. Goodwin et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin
- (2011) David W. Boulton et al. CLINICAL PHARMACOKINETICS
- Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
- (2011) Nir Barzilai et al. CURRENT MEDICAL RESEARCH AND OPINION
- Glucose-Dependent Insulinotropic Polypeptide: A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans
- (2011) M. Christensen et al. DIABETES
- Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin*
- (2011) U. Graefe-Mody et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors and HbA1c target of
- (2011) K. Esposito et al. DIABETES OBESITY & METABOLISM
- Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans
- (2011) B. Ahrén et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1
- (2010) E M Migoya et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
- (2010) M. Ligueros-Saylan et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
- (2010) C. F. Deacon DIABETES OBESITY & METABOLISM
- Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
- (2010) André J. Scheen et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus
- (2009) K. Aaboe et al. DIABETES OBESITY & METABOLISM
- Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes
- (2009) Bo Ahrén et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies
- (2009) Richard E. Pratley et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials
- (2009) M. Monami et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects
- (2008) R CHRISTOPHER et al. CLINICAL THERAPEUTICS
- Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited
- (2008) B. F. Burkey et al. DIABETES OBESITY & METABOLISM
- Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes
- (2008) P. V. Højberg et al. DIABETOLOGIA
- Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function
- (2008) Kei Ohnuma et al. TRENDS IN IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation